LEXX

Company Overview — What Does Lexaria Bioscience Corp. Do?

Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada. Lexaria Bioscience Corp. (LEXX) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Christopher A. Bunka and employs approximately 7 people. With a market capitalization of $22M, LEXX is one of the notable companies in the Healthcare sector.

Lexaria Bioscience Corp. (LEXX) Stock Rating — Reduce (April 2026)

As of April 2026, Lexaria Bioscience Corp. receives a Reduce rating with a composite score of 28.0/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.LEXX ranks #2,993 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Lexaria Bioscience Corp. ranks #432 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

LEXX Stock Price and 52-Week Range

Lexaria Bioscience Corp. (LEXX) currently trades at $0.98. The stock gained $0.08 (8.3%) in the most recent trading session. The 52-week high for LEXX is $1.90, which means the stock is currently trading -48.3% from its annual peak. The 52-week low is $0.46, putting the stock 113.0% above its annual trough. Recent trading volume was 93K shares, suggesting relatively thin trading activity.

Is LEXX Overvalued or Undervalued? — Valuation Analysis

Lexaria Bioscience Corp. (LEXX) carries a value factor score of 26/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 5.45x, versus the sector average of 2.75x. The price-to-sales ratio is 46.32x, compared to 1.66x for the average Healthcare stock.

At current multiples, Lexaria Bioscience Corp. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Lexaria Bioscience Corp. Profitability — ROE, Margins, and Quality Score

Lexaria Bioscience Corp. (LEXX) earns a quality factor score of 14/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -239.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -178.7% versus the sector average of -33.1%.

On a margin basis, Lexaria Bioscience Corp. reports gross margins of 99.5%, compared to 71.5% for the sector. The operating margin is -1733.1% (sector: -66.1%). Net profit margin stands at -1737.2%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -100.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

LEXX Debt, Balance Sheet, and Financial Health

Lexaria Bioscience Corp. has a debt-to-equity ratio of 34.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 3.68x, indicating strong short-term liquidity.

LEXX has a beta of 0.90, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Lexaria Bioscience Corp. is 27/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Lexaria Bioscience Corp. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Lexaria Bioscience Corp. reported revenue of $531,923 and earnings per share (EPS) of $-0.07. Net income for the quarter was $-11M. Gross margin was 99.5%. Operating income came in at $-11M.

In Q1 2026, Lexaria Bioscience Corp. reported revenue of $0. Net income for the quarter was $-2M. Operating income came in at $-2M.

In FY 2025, Lexaria Bioscience Corp. reported revenue of $705,923. Net income for the quarter was $-12M. Gross margin was 99.6%. Revenue grew 52.0% year-over-year compared to FY 2024. Operating income came in at $-12M.

In Q3 2025, Lexaria Bioscience Corp. reported revenue of $174,000. Net income for the quarter was $-4M. Gross margin was 100.0%. Revenue grew 107.1% year-over-year compared to Q3 2024. Operating income came in at $-4M.

Over the past 8 quarters, Lexaria Bioscience Corp. has demonstrated a growth trajectory, with revenue expanding from $84,000 to $531,923. Investors analyzing LEXX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

LEXX Dividend Yield and Income Analysis

Lexaria Bioscience Corp. (LEXX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

LEXX Momentum and Technical Analysis Profile

Lexaria Bioscience Corp. (LEXX) has a momentum factor score of 28/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 40/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 62/100 reflects moderate short selling activity.

LEXX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Lexaria Bioscience Corp. (LEXX) ranks #432 out of 838 stocks based on the Blank Capital composite score. This places LEXX in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing LEXX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full LEXX vs S&P 500 (SPY) comparison to assess how Lexaria Bioscience Corp. stacks up against the broader market across all factor dimensions.

LEXX Next Earnings Date

No upcoming earnings date has been announced for Lexaria Bioscience Corp. (LEXX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy LEXX? — Investment Thesis Summary

The quantitative profile for Lexaria Bioscience Corp. suggests caution. The quality score of 14/100 flags below-average profitability. The value score of 26/100 indicates premium valuation. Momentum is weak at 28/100, a headwind for near-term performance. High volatility (stability score 27/100) increases portfolio risk.

In summary, Lexaria Bioscience Corp. (LEXX) earns a Reduce rating with a composite score of 28.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on LEXX stock.

Related Resources for LEXX Investors

Explore more research and tools: LEXX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare LEXX head-to-head with peers: LEXX vs AZN, LEXX vs SLGL, LEXX vs VMD.